Course and predictors of work productivity in gout — results from the NOR-Gout longitudinal 2-year treat-to-target study
Authors' conclusion
In patients with gout who were intensively treated to the sUA target, work productivity and activity impairment were largely unchanged and at 1 year predicted by comorbidities and patient concerns about medication.
Study context
- Population
- Patients with gout with a recent flare and serum urate (sUA) >360 µmol/l on escalating ULT by treat-to-target (NOR-Gout)
- Outcome
- Longitudinal changes in and predictors of work productivity (WPAI)
- Follow-up
- 2 years
Methodological detailslongitudinal, treat-to-target, tight-control visits
- Longitudinal
- Treat-to-target
- Tight-control visits
Main finding
As reported in the abstract
WPAI scores at baseline
Work missed (absenteeism)
5.0%
Work impairment (presenteeism)
19.1%
Overall work impairment
21.4%
Activity impairment
32.1%
Observational data: associations, not effects.
Further findings
Predictors of Work Productivity and Activity Impairment (WPAI) scores · year 1
- Comorbidities not cross-sectionally associated with WPAI scores at baseline, but predicted worse work impairment and activity impairment at year 1
- BMQ concerns subscale at baseline independently predicted worse overall work impairment and activity impairment at year 1
Original publication
Course and predictors of work productivity in gout — results from the NOR-Gout longitudinal 2-year treat-to-target study. Rheumatology (Oxford). Published 21 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →